Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Investor & Media Contacts:BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 9,450 shares of its common stock under the Company's 2023 Inducement Plan.
加利福尼亞州布里斯班，2024年12月6日（全球新聞熱線）—— Tempest Therapeutics, Inc.（納斯達克：TPST），一家臨床階段生物技術公司，正在開發首個針對癌症的靶向和免疫介導治療，今天宣佈，該公司的董事會薪酬委員會向一名員工授予了一份非合格股票期權，允許該員工在公司2023年引入計劃下購買總計9,450股普通股。
The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of such employee's start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
這些股票期權將在四年內逐步歸屬，其中25%的期權將在該員工入職一週年時歸屬，其餘每月歸屬1/48的總股數，前提是該員工在每個歸屬日期繼續任職。
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at .
關於Tempest Therapeutics
Tempest Therapeutics是一家臨床階段生物技術公司，正在推進一系列多樣化的小分子產品候選者，這些候選者具有腫瘤靶向和/或免疫介導機制，具有治療廣泛腫瘤的潛力。該公司的新穎項目涵蓋從早期研究到在一線癌症患者中進行的隨機全球研究的後期調查。Tempest總部位於加利福尼亞州布里斯班。有關Tempest的更多信息，請訪問該公司的官方網站。
Investor & Media Contacts:
投資者與媒體聯繫人：
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
西爾維婭·惠勒
惠爾豪斯生命科學顧問
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
阿爾賈奈·雷諾茲
惠爾豪斯生命科學顧問
areynolds@wheelhouselsa.com
1 If approved by the FDA
1 如果獲得FDA批准
譯文內容由第三人軟體翻譯。